



Pr François PATTOU

François Pattou is 54 years old. Entered as a student at the school of medicine of Lille in 1984, he became professor of general surgery in 2002, then head of the department of general and endocrine surgery at the Lille University Hospital in 2006. Since 2001, he has head of the UMR 859 "Biotherapies of diabetes", an INSERM research team, part of the excellence laboratory LABEX EGID (European genomic institute for diabetes). For 20 years, his research has focused on the development of new interventional treatments for diabetes and metabolic diseases, and more particularly on cell therapy and metabolic surgery. François Pattou has obtained as principal investigator more than 30 research contracts with French institutional partners (PIA, PHRC, ANR) and international (FP7, IMI, JDRF). This research has given rise to 250 international publications. François Pattou has also received several awards including a grand prize from the Academy of Medicine for his work on cell therapy for diabetes. He coordinates several clinical trials for the surgical treatment of type 2 diabetes and obesity.

## Master of Biology and Health Lectures

### Abstract from diabetes and obesity Wednesday March 10, 2021 - 6:15 pm

#### Translational research and diabetes : the odyssey of medical innovation

The many steps that led us to a crazy idea - from treating type 1 diabetes through cell transplantation - to effective therapy and health insurance coverage, will be presented at this lecture.

Some references :

- **Pattou F**, Kerr-Conte J, Wild D, In vivo imaging of transplanted human beta cells with GLP1 Rc scan. *New Engl J Med* 2010;363:1989.
- Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, Beaucamps C, Delalleau N, Popescu I, Malaisse W, Sener A, Deprez B, Abderrahmani A, Staels B, **Pattou F**. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. *Nature Med* 2015;21(5):512.
- Baud G, Daoudi M, Hubert T, Raverdy V, Pigeyre M, Hervieux E, Devienne M, Ghunaim M, Queon A, Pigny P, Klein A, Caiazzo R, **Pattou F**. Bile diversion decreases sodium dependent glucose intestinal uptake after Roux-en-Y Gastric Bypass (RYGB). *Cell Metab* 2016 23, 547-553
- Vantyghem MC, Chetboun M, Gmyr V, Jannin A, Espiard S, Le Mapihan K, Raverdy V, Delalleau N, Machuron F, Hubert T, Frimat M, Van Belle E, Hazzan M, Pigny P, Noel C, Caiazzo R, Kerr-Conte J, **Pattou F**. Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study. *Diabetes Care*. 2019 Nov;42(11):2042.
- Vantyghem MC, de Koning EJP, **Pattou F**, Rickels MR. Advances in  $\beta$ -cell replacement therapy for the treatment of type 1 diabetes. *Lancet*. 2019 Oct 5;394(10205):1274-1285.

See you on March 10, 2021 - 6:15 pm